New modalities are poised to comprise more than 30% of pipelines at major pharma companies. Highlighting this trend, BIO Asia-Taiwan 2022 features several sessions involving new modalities, including a New Modalities to Cure session with lectures from Tracy Humphries, mRNA Segment Marketing Leader of Cytiva; and Dr. Tsai-Kun Li, Vice President of the Development Center for Biotechnology(DCB).
Also scheduled is a session focused on advances in cell and gene therapy, headed by Dr. Hong-Nerng Ho, General Consultant and Chair Professor at Taipei Medical University and Director of the Research Center for Cell Therapy and Regeneration Medicine; and including talks from Dr. Joseph Liu, Commercial Head of Cell and Gene Therapy for the Asia Pacific Region at Novartis; Dr. William Xu, Medical Strategy Director at IQVIA; and Dr. David Loong, Senior Consultant for Novel Modalities Asia Pacific and Bioprocessing Strategy at Merck Life Science. This will be followed by a panel discussion including additional panelists Susy Liang, President of Taiwan Hitachi Asia Pacific, and others.
Register today to catch up with the latest developments in new modalities!
Who should attend:
Executives in pharma and biotech engaged in new modalities development.
Those seeking outreach and collaboration with external partners.
R&D staff in academia or research seeking to follow the latest
trends in new modalities.